Dr. Rahul Kushwah reports

PREDICTMEDIX AI ANNOUNCES MULTI-VERTICAL GROWTH STRATEGY TO BECOME AN AI HEALTH-TECHNOLOGY LEADER

Predictmedix AI Inc. today outlined a strategic plan to evolve from a single-product health-screening company into a diversified, AI-driven health-technology enterprise with three complementary growth platforms.

Three growth platforms

Clinical-trial AI platform -- primary near-term driver

Predictmedix is developing an adaptive AI engine designed to simulate, optimize and predict outcomes across multisite clinical trials -- addressing a global clinical trials market projected to reach $123.5-billion (U.S.) by 2030, growing at a CAGR (compound annual growth rate) of approximately 6.5 per cent from 2024 to 2030.

The software-as-a-service-based platform is intended to provide trial simulation, cross-trial learning, cost/outcome modelling and full regulatory traceability.

SmartHealth AI stations -- global commercialization

The company's contactless, screening systems have demonstrated approximately 95-per-cent accuracy in detecting impairment, infectious disease and multiple vital signs, supported by independent, multicentre clinical validation. Predictmedix is assessing regulatory requirements in multiple jurisdictions, including Southeast Asia, and plans to initiate formal medical-device certification processes as a next step toward global deployment for enterprise health and safety, hospital triage, and government health programs.

Consumer vital scanning mobile application -- direct-to-consumer entry

A planned mobile application will leverage Predictmedix's patented imaging technology to deliver vital sign monitoring through a smart phone, extending the company's platform into the growing digital health and telehealth markets.

Strategic rationale

• Recurring revenue potential: SaaS subscriptions for the clinical-trial AI platform; screening-as-a-service for enterprises and hospitals; consumer subscriptions for the mobile app;
• Defensible IP: proprietary adaptive-simulation engine and patented multispectral imaging algorithms;
• Large addressable markets: the global AI in health care market was estimated at $26.6-billion (U.S.) in 2024 and is projected to reach approximately $187.7-billion (U.S.) by 2030, growing at a approximately 38.6-per-cent CAGR (compound annual growth rate) from 2025 to 2030.

"Our validated smarthealth technology provides the data, AI engine and market credibility to scale across enterprise, clinical research and consumer segments," said Dr. Rahul Kushwah, chief operating officer of Predictmedix. "This multivertical approach is designed to diversify revenue and support sustainable long-term growth for our shareholders."

Details of the company's recent product validations, pilot programs and strategic partnerships can be found in earlier press releases at the company's website.

About Predictmedix AI Inc.

Predictmedix AI is an emerging provider of rapid health screening and remote patient care solutions globally. The company's safe entry stations -- powered by a proprietary artificial intelligence (AI) -- use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue or various mental illnesses. Predictmedix AI's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes.

We seek Safe Harbor.